


What is claimed is:

1. A compound of Formula (I)



5

or a pharmaceutically acceptable salt or solvate thereof

wherein

10 R^1 is H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} thioalkyl, cyano, halo, C_{3-7} cycloalkyl, $-C_{1-6}$ alkylene- C_{3-7} cycloalkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is $C(D)NR^3R^4$, $D'-D''(R^3)(R^4)$ or $CH_2NR^3R^4$

D' is CH_2 or a bond;

D'' is C, C-OH or CH

15

wherein

said C is attached to R^3 by a single or double bond;

said C is attached to R^4 by a single or double bond;

provided that

C is not attached to both R^3 and R^4

20

by double bonds;

said CH is attached to R^3 and R^4 by single bonds;

said C of C-OH is attached to R^3 and R^4 by single bonds;

D is O or S;

25

R^3 and R^4 are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-6}$ hydroxyalkyl, $-C_{1-4}$ alkylene-O- C_{1-4} alkyl, $-C_{1-3}$ alkylene- C_{1-6} alkyl,

thioalkyl, -C₂₋₆alkylidene-(C₁₋₄alkoxy)₂, C₃₋₇cycloalkyl, -C₁₋₆alkylene-C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₃₋₆alkynyl, -C₁₋₆alkylene-CN, -C₁₋₆alkylene-heterocyclo and -C₁₋₆alkylene-aryl;

5 wherein said aryl of said -C₁₋₆alkylene-aryl is optionally substituted with one to three of the same or different substituents selected from the group consisting of fluoro, chloro, bromo, cyano, nitro, C₁₋₄alkyl and C₁₋₃alkoxy;

10 or

R³ and R⁴ together with the nitrogen to which they are attached form a five or six-membered heterocycle,

15 said heterocycle optionally containing one additional heteroatom selected from the group consisting of N, S and O; and


said heterocycle optionally substituted with one or more groups selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, aryl, -C₁₋₄alkylene-aryl, pyridyl and halogen;

20 wherein said aryl of said -C₁₋₄alkylene-aryl is optionally substituted with one to three of the same or different substituents selected from the group consisting of fluoro, chloro, bromo, cyano, nitro and C₁₋₃alkoxy;

25

30 X is C;
Y is C;

A is




wherein

5 X^1 is N and is attached to X;

Y^1 is N and is attached to Y;

G is



10 wherein

Y^2 is CE^1 and is attached to Y^1 ;

J is a bond ;

Z^1 is CE^3 and is attached to Z;

wherein

15

E^1 and E^3 together form $N(CH)_3$,

optionally substituted with halogen,

-CN, C_1 - C_4 alkyl, C_3 -

C_6 cycloalkyl, substituted or

20

unsubstituted phenyl,

hydroxy, C_1 - C_4 alkoxy, SH,

C_1 - C_4 thioalkyl, NH_2 , $NH(C_1$ -

C_4 alkyl) or $N(C_1$ - C_4 alkyl) $_2$;

5 Z is N-V, wherein V is phenyl, 2-pyridyl or 3-pyridyl substituted with two to three of the same or different substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₆thioalkyl, C₁₋₄haloalkyl, halogen, N(C₁-C₄alkyl)₂ and CN.

2. A compound according to claim 1 wherein V is phenyl or 3-pyridyl and is substituted with two to three of the same or different substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₆thioalkyl, C₁₋₄haloalkyl, halogen, N(C₁-C₄alkyl)₂ and CN; said substituents attached at the 2, 4 or 6-positions of said phenyl or said 3-pyridyl.
3. A compound according to claim 1 wherein V is 2-pyridyl and is substituted with two of the same or different substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₆thioalkyl, C₁₋₄haloalkyl, halogen, N(C₁-C₄alkyl)₂ and CN; said substituents attached at the 3 and 5-positions of said 2-pyridyl.
4. A compound according to claim 1 wherein R¹ is C₁₋₆alkyl or C₁₋₆haloalkyl.
5. A compound according to claim 1 wherein R¹ is methyl or trifluoromethyl.
6. A compound according to claim 1 wherein R² is C(D)NR³R⁴ and D is O.
7. A compound according to claim 1 wherein R² is CH₂N R³R⁴.
8. A compound according to claim 1 wherein R² is D'-D''(R³)(R⁴), D is a bond and D'' is C-OH.
9. A compound according to claim 1 wherein R² is D'-D''(R³)(R⁴), D is a bond and D'' is C or CH.
10. A compound according to claim 1 wherein R³ and R⁴ are each independently selected from the group consisting of H, C₁₋₆alkyl, C₁₋₆haloalkyl, -C₁₋₆hydroxyalkyl, -C₁₋₄alkylene-O-C₁₋₄alkyl, -C₁₋₃alkylene-C₁₋₆thioalkyl, -C₂₋₆alkylidene-(C₁₋₄alkoxy)₂, C₃₋₇cycloalkyl, -C₁₋₆alkylene-C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₃₋₆alkynyl and -C₁₋₆alkylene-CN.
11. A compound according to claim 1 wherein R³ and R⁴ together with the nitrogen to which they are attached form a five or six-membered heterocycle.
12. A compound according to claim 1 wherein V is 2, 4, 6-trimethylphenyl.

13. A compound according to claim 1 wherein V is 2,4-dichlorophenyl.
14. A compound according to claim 1 wherein E¹ and E³ together form N(CH)₃ optionally substituted with halogen, methoxy, methyl or nitrile.
15. A compound according to claim 1 wherein R² is CH₂NR³R⁴, R³ is ethyl or propyl, R⁴ is -(CH₂)₂-phenyl, E¹ and E³ together form N(CH)₃ optionally substituted with halogen, methoxy, methyl or nitrile.
16. A compound according to claim 1 wherein R² is CH₂NR³R⁴, R³ is ethyl or propyl, R⁴ is -(CH₂)₂-phenyl, E¹ and E³ together form N(CH)₃ optionally substituted with halogen.
17. A compound or pharmaceutically acceptable salt of solvate thereof selected from the group consisting of
 - Ethyl-[2-methyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,7,8-tetraaza-cyclopenta[α]inden-3-ylmethyl]-phenethyl-amine;
 - Cyclobutylmethyl-[2-methyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,7,8-tetraaza-cyclopenta[α]inden-3-ylmethyl]-propyl-amine;
 - [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-phenethyl-propyl-amine;
 - [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[α]inden-3-ylmethyl]-cyclobutylmethyl-propyl-amine;
 - [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-ethyl-phenethyl-amine;
 - 8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-3-(3-phenyl-pyrrolidin-1-ylmethyl)-8*H*-1,3a,7,8-tetraaza-cyclopenta[α]indene;
 - Cyclopropylmethyl-propyl-[2-trifluoromethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-amine;
 - Phenethyl-[2-trifluoromethyl-8-(2,4,6-trimethyl-phenyl)-8*H*-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-(3,3,3-trifluoro-propyl)-amine;
 - [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-phenethyl-propyl-amine;
 - [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-ethyl-phenethyl-amine; and

[8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[*a*]inden-3-ylmethyl]-(2-methoxy-1-methoxymethyl-ethyl)-amine.

18. A method of treating depression, anxiety, affective disorders, post-traumatic stress disorder, post-operative stress, headache, drug addiction, eating disorders and obesity, sudden death due to cardiac disorders, irritable bowel syndrome, hypertension, syndrome X, inflammatory disorders, stress-induced immune suppression, infertility, stress-induced insomnia and other sleep disorders, seizures, epilepsy, stroke and cerebral ischemia, traumatic brain injury, yet other disorders requiring neuroprotection, drug or alcohol withdrawal symptoms, other disorders including tachycardia, congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, ulcers, diarrhea and post-operative ileus comprising the administration of a pharmaceutical composition comprising a compound according to claim 1.